Education
About Us
Working with TipRanks
Follow Us
Pacira (PCRX)
NASDAQ:PCRX
PCRX Stock Chart & Stats
$21.77
-$0.08(-0.43%)
At close: 4:00 PM EST
$21.77
-$0.08(-0.43%)
Day’s Range― - ―
52-Week Range$18.80 - $27.64
Previous CloseN/A
Volume54.84K
Average Volume (3M)924.36K
Market Cap
$936.57M
Enterprise Value$1.21B
Total Cash (Recent Filing)$246.33M
Total Debt (Recent Filing)$425.31M
Price to Earnings (P/E)48.8
Beta0.87
Next Earnings
Feb 26, 2026EPS Estimate
0.91Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.70
Shares Outstanding43,021,275
10 Day Avg. Volume713,463
30 Day Avg. Volume924,361
Financial Highlights & Ratios
PEG Ratio0.03
Price to Book (P/B)1.12
Price to Sales (P/S)1.24
P/FCF Ratio4.87
Enterprise Value/Market Cap1.30
Enterprise Value/Revenue1.69
Enterprise Value/Gross Profit2.14
Enterprise Value/Ebitda8.21
Forecast
1Y Price Target
$30.33Price Target Upside39.32% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering6
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical Synergies Enabling Opioid-free CareAnalyst points out that combining Iovera before surgery with Exparel during surgery, together with complementary product approvals, can enable higher rates of opioid-free outcomes and encourage clinician adoption.
NOPAIN Program AdoptionAnalyst highlights that expanded access through the NOPAIN program and nerve-block approvals could broaden Exparel's use in surgical settings and support renewed revenue momentum.
Share Repurchase And Capital ReturnsAnalyst notes that a sizable share repurchase program reduces outstanding shares and supports shareholder value while signaling confidence in the core business.
Bears Say
Generic Competition And Patent Litigation RiskAnalyst warns that ANDA challengers and recent adverse patent rulings create meaningful risk of generic entry that could substantially erode Exparel-derived revenue.
Near-term Sales Softness And Limited UpsideAnalyst highlights that slightly below-consensus revenue and flat performance for companion products point to constrained revenue upside and may keep investor sentiment muted until growth proves durable.
Reimbursement And Contracting UncertaintyAnalyst cautions that changes in reimbursement policy or purchasing contracts could materially reduce revenue and undermine the benefit of uptake initiatives.
Pacira Pharmaceuticals News
PCRX FAQ
What was Pacira’s price range in the past 12 months?
Pacira lowest stock price was $18.80 and its highest was $27.64 in the past 12 months.
What is Pacira’s market cap?
Pacira’s market cap is $936.57M.
When is Pacira’s upcoming earnings report date?
Pacira’s upcoming earnings report date is Feb 26, 2026 which is in 9 days.
How were Pacira’s earnings last quarter?
Pacira released its earnings results on Nov 06, 2025. The company reported $0.7 earnings per share for the quarter, beating the consensus estimate of $0.677 by $0.023.
Is Pacira overvalued?
According to Wall Street analysts Pacira’s price is currently Undervalued.
Does Pacira pay dividends?
Pacira does not currently pay dividends.
What is Pacira’s EPS estimate?
Pacira’s EPS estimate is 0.91.
How many shares outstanding does Pacira have?
Pacira has 43,021,275 shares outstanding.
What happened to Pacira’s price movement after its last earnings report?
Pacira reported an EPS of $0.7 in its last earnings report, beating expectations of $0.677. Following the earnings report the stock price went up 4.502%.
Which hedge fund is a major shareholder of Pacira?
Currently, no hedge funds are holding shares in PCRX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Pacira Pharmaceuticals Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$30.33 (39.32% Upside)
$30.33 (39.32% Upside)
Blogger Sentiment
Bullish
PCRX Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 105.0K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.8%
Last 30 Days ▼ 5.2%
Last 30 Days ▼ 5.2%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-17.94%
12-Months-Change
Fundamentals
Return on Equity
2.90%
Trailing 12-Months
Asset Growth
-14.73%
Trailing 12-Months
Company Description
Pacira
Pacira BioSciences, Inc. provides non-opioid pain management and regenerative health solutions for healthcare practitioners and their patients in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid handheld cryoanalgesia device used to produce controlled doses of cold temperature only to targeted nerves. It also develops proprietary multivesicular liposome, a drug delivery technology that encapsulates drugs without altering their molecular structure. The company was formerly known as Pacira Pharmaceuticals, Inc. and changed its name to Pacira BioSciences, Inc. in April 2019. Pacira BioSciences, Inc. was incorporated in 2006 and is headquartered in Tampa, Florida.
PCRX Company Deck
PCRX Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted strong revenue growth, improved manufacturing efficiencies, and significant pipeline expansion. However, some challenges were noted with Zilretta's slower-than-expected sales growth and discount impacts from new GPO agreements affecting pricing. Elective procedure market growth was also described as sluggish.View all PCRX earnings summariesPCRX Stock 12 Month Forecast
Average Price Target
$30.33
▲(39.32% Upside)
Technical Analysis
Avadel Pharmaceuticals
―
Supernus Pharmaceuticals
―
ANI Pharmaceuticals
―
Amphastar Pharmaceuticals
―
Collegium Pharmaceutical
―
Ownership Overview
3.47% Insiders
24.38% Mutual Funds
12.35% Other Institutional Investors
28.39% Public Companies and
Individual Investors